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I. INTRODUCTION 
“It is a chemical entity, but DNA’s importance flows from its ability 
to encode and transmit the instructions for creating humans.  Life’s 
instructions ought not be controlled by legal monopolies created at the 
whim of Congress or the courts,” wrote Dr. James Watson, one of the 
Physiology or Medicine Nobel Prize winners in 1962 for the discovery of 
the structure of DNA.1  Dr. Watson also proclaimed, “[i]n years to come, 
with the right advances in genetic engineering, we may well be able to 
treat or rectify mental disabilities and physical diseases which today are 
deemed incurable.  Such hope is all the more reason that scientific 
research on human genes should not be impeded by the existence of 
unnecessary patents.”2  Indeed this viewpoint may be well-reasoned, but 
determining whether a patent is necessary or unnecessary is far too 
subjective to be reasonably practical. 
Patents are fundamentally necessary for advancements in scientific 
research; stating anything to the contrary opposes both reality and the 
patent system’s purpose.3  However, after the Supreme Court decision 
that largely abolished gene patentability, the recent Federal Circuit 
decision, and new patent laws there are unresolved questions as to the 
extent patents in the field of genetic testing will continue to exist and what 
the future holds for the underlying research.4  The biotechnology industry 
has been shaken to its core numerous times over the past several years, 
and there is mounting pressure for stability, which is likely only 
obtainable through a legislative solution.5  While this Note does not 
 
1 Brief for James D. Watson as Amici Curiae Supporting Neither Party at 2, Ass’n for 
Molecular Pathology v. USPTO, 689 F.3d 1303 (2012) (No. 2010-1406), available at 
https://www.aclu.org/files/assets/2012_06_15_-_james_d__watson_brief_on_remand.pdf; 
James Watson – Biographical, NOBELPRIZE.ORG, 
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1962/watson-bio.html (last 
visited Oct. 30, 2013). 
2 Brief for James D. Watson, supra note 1, at 6 (emphasis added). 
3 Adrian Tombling, Ban on Human Gene Patents is Baffling but it Won’t Impede Biotech 
Research, THE GUARDIAN (June 18, 2013, 8:51 PM), 
http://www.theguardian.com/science/blog/2013/jun/18/ban-human-gene-patents-biotech-
research. 
4 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013); 
BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. v. Ambry Genetics Corp., 
2014 U.S. App. LEXIS 23692, at *1 (Fed. Cir. Dec. 17, 2014). 
5 Austin Donohue, USPTO Issues New Myriad Guidance, BIOTECHNOW (Feb. 4, 2015), 
http://www.biotech-now.org/public-policy/patently-biotech/2015/02/bio-deputy-general-
counsel-remarks-on-revised-eligibility-guidance (“If anything, this decision . . . is a reminder 
that the PTO’s efforts to bring stability to this area of the law could easily be undone by the 
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propose such legislation, this Note nonetheless addresses several 
practical implications affecting the industry and patent-holders as a result 
of the Supreme Court holding that isolated genes are unpatentable and 
the Federal Circuit holding that part of Myriad’s patent-eligible subject 
matter did not add enough to wholly make the genetic testing claims 
patent-eligible .6 
Specifically, this Note addresses how new provisions in the Leahy-
Smith America Invents Act (“AIA”) changed the practice of patent law 
and considerations that courts need to be cognizant of when issuing future 
rulings.  Part II delves into the fundamentals of patent law that pertain to 
the subsequent discussion and sets the stage for the notion that obtaining 
a patent does not unequivocally grant absolute rights.  Part III addresses 
the background case law that led to the recent monumental Supreme 
Court decision, Ass’n for Molecular Pathology v. Myriad Genetics, Inc.,7 
the series of guidance issued by the United States Patent and Trademark 
Office (“USPTO”), and the most recent authority from the Federal Circuit 
in BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. v. 
Ambry Genetics Corp.8  Part IV discusses the AIA and how it altered the 
practice of patent law with respect to procedures for challenging the 
validity of patents within the USPTO itself through post-grant 
proceedings.  Part V highlights that these new post-grant proceedings 
alongside Myriad lead to less obvious, but still significant trouble for the 
industry’s leading patent-holders.  Finally, this Note concludes that the 
practice of patent law is at a very pivotal and delicate point and that it 
must evolve to continue promoting research generally, and specifically in 
the genetic testing industry.  This will be accomplished if genetic tests, 
as so-called methods, remain patent-eligible subject matter despite the 
fact that genes are now unpatentable. 
 
 
next Federal Circuit decision, or the one after that.  We are afraid that we will be prosecuting 
applications on a shifting slate for some time to come.  We need a more stable solution going 
forward.”). 
6 Myriad Genetics, Inc., 133 S. Ct. at 2107; Ambry Genetics Corp., 2014 U.S. App. 
LEXIS 23692, at *20. 
7 Myriad Genetics, Inc., 133 S. Ct. at 2107. 
8 Ambry Genetics Corp., 2014 U.S. App. LEXIS 23692, at *1; Memorandum from 
Andrew H. Hirshfeld, Deputy Commissioner for Patent Examination Policy, for Patent 
Examining Corps (Mar. 4, 2014), available at 
http://www.uspto.gov/patents/law/exam/myriad-mayo_guidance.pdf. 
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II. PATENT LAW BACKGROUND 
Pursuant to the Constitution, “Congress shall have the power to . . . 
promote the [p]rogress of [s]cience and useful [a]rts, by securing for 
limited [t]imes to [a]uthors and [i]nventors the exclusive [r]ight to their 
respective [w]ritings and [d]iscoveries.”9  This provision gave rise to the 
United States Patent Act of 1790, from which the first patents were born.10  
A patent is defined as a “property right granted by the Government of the 
United States of America to an inventor []to exclude others from making, 
using, offering for sale, or selling the invention throughout the United 
States . . . for a limited time in exchange for public disclosure of the 
invention.”11  The United States Patent Act was largely unchanged until 
1952 when the USPTO began classifying patents into three categories: 
utility patents, design patents, and plant patents.12  The general focus of 
this Note is on utility patents, which are granted for the invention of “a 
new and useful method, process, machine, device, manufactured item, or 
chemical compound” or any new and useful improvement thereof.13  In 
modern times, courts categorize chemical compounds as compositions of 
matter and define them as tangible items comprising two or more 
substances.14  On the other hand, a patented method consists of a series of 
steps that is only infringed upon if each and every step is performed. 
In order to receive a utility patent, an inventor publicly discloses his 
invention in exchange for a twenty-year period of exclusivity to use and 
practice the invention from the date that the patent application is filed 
with the USPTO.15  Through the lengthy process of obtaining a patent, the 
inventor submits to the USPTO a patent application ideally containing 
claims that specifically identify the proposed invention.  At the USPTO, 
 
9 U.S CONST. art. I, § 8, cl. 8. 
10 Press Release, USPTO, The U.S. Patent System Celebrates 212 Years, #02-26 (Apr. 9, 
2002), available at http://www.uspto.gov/news/pr/2002/02-26.jsp. 
11 Patent FAQs, USPTO, http://www.uspto.gov/inventors/patents.jsp (last visited Apr. 
19, 2014). 
12 “A patent for an invention is the grant of a property right to the inventor, issued by the 
United States Patent and Trademark Office.”  General Information Concerning Patents, 
USPTO (Oct. 2014), http://www.uspto.gov/patents-getting-started/general-information-
concerning-patents. 
13 Mary Bellis, Utility Patent, ABOUT.COM, 
http://inventors.about.com/od/definations/g/Utility_Patent.htm (last visited May 13, 2015). 
14 35 U.S.C. § 101 (2012); Andrew Chadeayne, Composition of Matter Claims, 
INVENTING PATENTS (Sept. 17, 2013), http://inventingpatents.com/composition-matter-
claims/. 
15 35 U.S.C. § 154(a)(2) (2012). 
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a patent examiner (“examiner”) reviews the patent application, and the 
invention is publicly disclosed when the USPTO publishes the patent 
application eighteen months after it is filed.16  The examiners 
communicate with inventors by sending office actions that include the 
examiner’s detailed analysis of the patent application, including reasons 
the inventor cannot yet receive a patent for the particular invention.17  For 
patent applications that adhere to all applicable provisions, examiners 
will issue a notice of allowance resulting in the grant of a patent, provided 
that the inventor pays the issue fee.18  The Supreme Court case Myriad, a 
focal point of this Note, deals primarily with one of those provisions for 
patentability—whether the subject matter itself is patentable. 
Generally speaking, Myriad pertains to “patent-eligible” subject 
matter defined under 35 U.S.C. § 101.19  This provision identifies four 
categories of patent-eligible subject matter: a process, a machine, a 
manufacture, and a composition of matter.20  Everything within the scope 
of a utility patent must fall within at least one of these four categories.21  
Genes, chemical compounds or compositions of matter, defined as the 
basic units of heredity responsible for all physical and inheritable 
characteristics of an organism, were therefore claimed in utility patents.22  
Examples of patent ineligible subject matter, or the so-called judicial 
exceptions, include: “laws of nature, physical or natural phenomenon, 
and abstract ideas.”23  Once an examiner or a court finds that claims are 
patent-eligible, the patentability inquiry proceeds to other provisions that, 
 
16 Id. § 122(b)(1) (explaining that patent applications are published eighteen months after 
filing and once published they are easily accessible on websites such as 
GOOGLE.COM/PATENTS or HTTP://PORTAL.USPTO.GOV/PAIR/PUBLICPAIR); Nonprovisional 
(Utility) Patent Application Filing Guide, USPTO (Jan. 2014), 
http://www.uspto.gov/patents/resources/types/utility.jsp. 
17 37 C.F.R. § 1.104 (2014). 
18 Id. § 1.311 (2014). 
19 35 U.S.C. § 101 (2012); Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 
S. Ct. 2107 (2013). 
20 35 U.S.C. § 101. 
21 Id.; Z. Peter Sawicki, Visala C. Goswitz & Amanda Prose, Patenting Biologicals: 
Myriad Issues and Options in the Wake of Myriad, BENCH & B. OF MINN., 24 (Sept. 2013), 
available at http://mnbenchbar-digital.com/mnbenchbar/september_2013?pg=24#pg24. 
22 Gene, DICTIONARY.COM, http://dictionary.reference.com/browse/gene (last visited 
Mar. 22, 2014); General Information Concerning Patents, supra note 12 (“A patent for an 
invention is the grant of a property right to the inventor, issued by the United States Patent 
and Trademark Office.”).  
23 Bilski v. Kappos, 130 S. Ct. 3218, 3225 (2010) (quoting Diamond v. Chakrabarty, 447 
U.S. 303, 309 (1980)). 
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for instance, assess novelty and nonobviousness.24 
For over thirty years before Myriad, the USPTO granted thousands 
of gene patents as compositions of matter.25  The USPTO even reaffirmed 
the issuance of such patents in 2001.26  But in Myriad, the Court 
essentially held that patents may no longer be granted for the simple 
discovery that a particular human gene sequence corresponds to a specific 
inheritable trait.27  Thus, without expressly acknowledging Dr. Watson’s 
views, the Court fundamentally agreed with him that genes should not be 
patentable, not because patents on genes are unnecessary, but because the 
discovery of a gene is unpatentable.28  However, courts have yet to abolish 
the patentability of genetic tests.29  The unresolved debate, then, is over 
whether the patentability of genetic tests has been implicitly abolished 
under certain circumstances.30  Myriad put forth a tremendous effort 
trying to maintain its foothold in this industry, but it seems these battles 
are ones that Myriad will not win.31 
Settlements of some disputes, along with the USPTO guidance and 
Ambry, leave the industry in a greater state of uncertainty in early 2015 
than on June 13, 2013 when Myriad was decided.32  Ambry signals early 
signs of trouble for the genetic testing industry because it shows courts 
will not hesitate to extend the unpatentability of genes to the also 
previously patentable methods that use those genes.33  As such, Ambry 
demonstrates how crucial the underlying patentability of genes was for 
the patentability of genetic tests of those genes.34  It may now be just a 
 
24 35 U.S.C. §§ 102, 103 (2012). 
25 Eric J. Rogers, Can You Patent Genes? Yes and No, 93 J. PAT. & TRADEMARK OFF. 
SOC’Y 19 (2010). 
26 66 Fed. Reg. 1092, 1092–94 (Jan. 5, 2001). 
27 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013). 
28 Id. 
29 Intellectual Property and Genomics, NAT’L GENOME HUMAN RESEARCH INST., 
http://www.genome.gov/19016590 (last updated Oct. 30, 2014). 
30 Leila Gray, U.S. Supreme Court Decision to Bar Gene Patents Opens Genetic Test 
Options, UW TODAY (June 20, 2013), http://www.washington.edu/news/2013/06/20/u-s-
supreme-court-decision-opens-genetic-test-options/. 
31 Andrew Pollack, Myriad Genetics Ending Patent Dispute on Breast Cancer Risk 
Testing, N.Y. TIMES (Jan. 27, 2015), http://www.nytimes.com/2015/01/28/business/myriad-
genetics-ending-patent-dispute-on-breast-cancer-risk-testing.html?_r=0. 
32 Id. 
33 Myriad Genetics, Inc., 133 S. Ct. at 2107; BRCA1- & BRCA2-Based Hereditary 
Cancer Test Patent Litig. v. Ambry Genetics Corp., 2014 U.S. App. LEXIS 23692, at *1 (Fed. 
Cir. Dec. 17, 2014). 
34 Id. 
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matter of time before genetic tests are unpatentable solely because genes 
themselves are unpatentable. 
 
III.  MYRIAD AND PATENT-ELIGIBLE SUBJECT MATTER 
A. Recent Case Law 
On June 16, 1980, the Supreme Court decided its first modern-day 
pivotal case in the area of patent-eligible subject matter.35  In Diamond v. 
Chakrabarty,36 the Court ruled “[a] live, human-made micro-organism is 
patentable subject matter under § 101.”37  Reviewing the legislative 
history, the Court opined that “Congress contemplated that patent laws 
should be given wide scope, and . . . broad construction.  While laws of 
nature, physical phenomena, and abstract ideas are not patentable [the 
claims here are to a] composition of matter — a product of human 
ingenuity ‘having a distinctive name, character[, and] use.’”38  This 
opinion was revolutionary for its time because a patent examiner 
previously rejected this patent application on the grounds that 
microorganisms are products of nature and that living things, such as 
microorganisms, are unpatentable subject matter.39  Yet, central to the 
Court rejecting that analysis, the inventor produced a new bacterium that 
had “markedly different characteristics” from bacteria found in nature.40  
The Court classified the bacterium as patent-eligible subject matter 
because those characteristics have the potential for significant utility.41  
Importantly, the Court explained that not all differences between 
something that is produced and something that is found in nature give rise 
to the level of “marked differences.”42  “Marked differences” must be 
“significant differences,” which are more than merely incidental or 
trivial.43 
Three decades later, in Bilski v. Kappos,44 the Court found that a 
claimed process to hedge risk in the energy business was unpatentable 
subject matter, and thus invalid, when it involved an abstract idea that 
 
35 Diamond v. Chakrabarty, 447 U.S. 303 (1980). 
36 Id. 
37 Id. at 305, 310. 
38 Id. (quoting Hartranft v. Wiegmann, 121 U.S. 609, 615 (1887)). 
39 Id. at 306. 
40 Id. at 310–11. 
41 Diamond, 447 U.S. at 310–11. 
42 Memorandum from Andrew H. Hirshfeld (Mar. 4, 2014), supra note 8. 
43 Id. 
44 130 S. Ct. 3218, 3231 (2010).   
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broadly preempted its use in all fields.45  Processes are patentable subject 
matter under 35 U.S.C. § 101, but in this case, the process was 
unpatentable because “[h]edging is a fundamental economic practice long 
prevalent in our system of commerce and taught in any introductory 
finance class.”46  The Court opined that the 1952 Patent Act did not 
expand the scope of patentable subject matter to include any series of 
steps as a process under 35 U.S.C. § 101, and that “[t]he patent 
application here can be rejected under our precedents on the 
unpatentability of abstract ideas.”47 
Two years after Bilksi, the Supreme Court held in Mayo 
Collaborative Services v. Prometheus Laboratories,48 that Prometheus’ 
medical test, which determined the proper dosage of a particular drug by 
measuring levels of the drug’s metabolites in a patient’s system, was not 
patentable.49  The Court reasoned that the processes covered by 
Prometheus’ patents did not transform otherwise unpatentable natural 
laws—in this case the correlation between the levels of the drug’s 
metabolites in the patient’s system with respect to the proper dosage the 
patient should be given—into patent-eligible applications complying 
with 35 U.S.C. § 101.50  Laws of nature, in addition to abstract ideas, are 
expressly excluded from that definition.51  In the instance of Prometheus’ 
medical test, the Court also found that the claims merely contained steps 
that involved “well-understood, routine, conventional activity previously 
engaged in by researchers in the field.”52  As a result, Prometheus’ patents 
were invalid, especially in light of Bilski. 
In a sense, invalidation is a way of stating that the examiners should 
not have granted either an entire patent or some claims therein; invalid 
claims are unenforceable against another entity for the purpose of an 
 
45 See Mayo Collaborative Servs. v. Prometheus Labs., 132 S. Ct. 1289, 1305 (2012). 
46 35 USC § 101 (2012); Bilski, 130 S. Ct. at 3231 (Rader, J., dissenting) (quoting In re 
Bilski, 545 F.3d 943, 1013 (2008)) (citing DIMITRIS N. CHORAFAS, INTRODUCTION TO 
DERIVATIVE FINANCIAL INSTRUMENTS 75–94 (2008); S. ROSS, R. WESTERFIELD, & B. JORDAN, 
FUNDAMENTALS OF CORPORATE FINANCE, 743–44 (8th ed. 2008); C. STICKNEY, R. WEIL, K. 
SCHIPPER, & J. FRANCIS, FINANCIAL ACCOUNTING: AN INTRODUCTION TO CONCEPTS, 
METHODS, AND USES, 581–82 (13th ed. 2010)). 
47 Bilski, 130 S. Ct. at 3231, 3249. 
48 132 S. Ct. 1289 (2012). 
49 Id. at 1294. 
50 Id. 
51 Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). 
52 Mayo, 132 S. Ct. at 1305. 
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infringement lawsuit.53  For example, according to Bilski and Prometheus, 
when the USPTO or courts invalidate a patent or some of its claims, the 
invalidated portions become worthless.  With that consideration in mind, 
the focus of this Note now turns to the keystone case-line involving 
Myriad Genetics, Inc. and its patents containing claims that are being 
litigated in numerous district courts. 
In 1996, Myriad Genetics located and sequenced two cancer 
susceptibility genes known as BRCA1 and BRCA2.54  Myriad developed 
and patented a genetic test for mutations in these genes and threatened to 
sue doctors and institutions that were using the BRCA deoxyribonucleic 
acid (“DNA”) sequences to test patients for genetic predisposition to 
breast, ovarian, and prostate cancer.55  The American Civil Liberties 
Union, the Association of Molecular Pathology, and several individual 
doctors, genetic counselors, scientific researchers, and patients 
challenged Myriad’s patents, arguing that human genes are not patent-
eligible and that certain patent claims were invalid.56  Finding that all of 
Myriad’s asserted DNA claims were products of nature and therefore 
patent ineligible under 35 U.S.C. § 101, the district court ruled against 
Myriad, but the Federal Circuit reversed on appeal.57  The Supreme Court 
granted certiorari, reaffirmed the district court’s holding by vacating the 
judgment of the Federal Circuit, and remanded the case to the Federal 
Circuit for further consideration in light of Prometheus.58 
On remand, a three-judge panel for the Federal Circuit again held 
that genomic DNA and the synthetic DNA molecule known as 
complementary DNA (“cDNA”) are both patent-eligible.59  The judges 
reasoned that genomic DNA can be extracted from its cellular 
environment using a number of well-established laboratory techniques, 
and a particular segment of DNA, such as a gene, can be excised or 
 
53 Mary L. Miller & Richard P. Vitek, Validity and Invalidity of Patent Claims, TECH. 
TRANSFER PRAC. MANUAL, available at 
http://www.autm.net/AM/Template.cfm?Section=Volume_3_TOC&Template=/CM/Conten
tDisplay.cfm&ContentID=2207. 
54 Dorothy R. Auth, ‘Myriad’ Aftermath: What Remains Patent Eligible?, 250 N.Y. L.J. 
6 (2013). 
55 Id. 
56 Id. 
57 Ass’n for Molecular Pathology v. USPTO, 689 F.3d 1303 (Fed. Cir. 2012); Ass’n for 
Molecular Pathology v. USPTO, 653 F.3d 1329 (Fed. Cir. 2011). 
58 Ass’n for Molecular Pathology v. USPTO, 132 S. Ct. 1794, 1794 (2012). 
59 Ass’n for Molecular Pathology, 689 F.3d at 1326. 
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amplified from the DNA to obtain the isolated DNA segment of interest.60  
Likewise, DNA molecules can also be synthesized in a laboratory.61  
However, in several processes analogous to those that occur in cells, 
naturally occurring sequences of genetic information serve as the 
template to create cDNA, a molecule that does not naturally exist because 
it is not a direct copy of the DNA sequence that it complements.62  As a 
result, the judges issued divergent opinions that raised questions about 
the precise contours of DNA’s patent eligibility, especially with respect 
to cDNA’s patent eligibility.63 
Judge Alan D. Lourie’s majority opinion upheld Myriad’s BRCA 
DNA claims on the grounds that the chemical differences generated 
during the isolation process between naturally occurring and isolated 
DNA sequences created a non-naturally occurring molecule.64  The claims 
at issue were from U.S. Patent 5,747,282, and recited: 
1. An isolated DNA coding for a BRCA1 polypep[]tide, said polypeptide having 
the amino acid sequence set forth in SEQ ID NO:2. 
2. The isolated DNA of claim 1, wherein said DNA has the nucleotide sequence 
set forth in SEQ ID NO:1. 
5. An isolated DNA having at least 15 nucleotides of the DNA of claim 1.
65
 
“SEQ ID NO:1” and “SEQ ID NO:2” correspond to the BRCA1 DNA 
coding region and the BRCA1 protein, respectively, and in Judge 
Lourie’s opinion the isolated DNA removed from its native cellular 
environment was manipulated in such a way that it was markedly 
different from what exists inside the body.66  Underscoring this notion was 
the idea that “courts must be cautious before adopting changes that 
disrupt the settled expectations of the inventing community.”67 
Judge Kimberly A. Moore joined the majority’s opinion for cDNA 
sequences, and concurred in judgment with respect to isolated DNA 
sequences, but wrote separately to explain her reasoning based on the 
USPTO’s history of awarding gene patents and the reliance interest of 
 
60 Id. at 1313. 
61 Id.  
62 Id. at 1313–14 (explaining that cDNA is generated from mRNA, and therefore only 
contains the coding regions of DNA known as exons, while DNA itself contains both exons 
and non-coding regions known as introns). 
63 Auth, supra note 54. 
64 Ass’n for Molecular Pathology, 689 F.3d at 1336. 
65 Id. at 1309; U.S. Patent No. 5,747,282 col. 153 (filed June 7, 1995). 
66 Ass’n for Molecular Pathology, 689 F.3d at 1328. 
67 Id. at 1333 (citing Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 28 
(1997)); see also Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1347 (Fed. Cir. 
2010) (en banc).  
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patent holders.68  Judge Moore opined that “to the extent the majority rests 
its conclusion on the chemical differences between genomic and isolated 
DNA (breaking the covalent bonds), I cannot agree that this is sufficient 
to hold that the claims to human genes are directed to patentable subject 
matter.”69  If this case were decided on a blank canvas, Judge Moore may 
have concluded that isolated DNA is not patentable subject matter, and 
yet again she echoes the majority’s sentiment that “we must be 
particularly wary of expanding the judicial exception to patentable 
subject matter where both settled expectations and extensive property 
rights are involved.”70   
Judge William C. Bryson, concurring in part and dissenting in part, 
argued the genetic similarities between naturally occurring and isolated 
BRCA DNA dwarfed any chemical differences between the two.71  Judge 
Bryson believed that although Myriad had valid claims to cDNA, Myriad 
did not have valid claims to the BRCA genes and associated gene 
fragments.72  In Judge Bryson’s opinion, “Myriad’s claims to the isolated 
BRCA genes seem . . . to fall clearly on the ‘unpatentable’ side of the line 
the Court drew in Chakrabarty.  Myriad is claiming the genes 
themselves, which appear in nature on the chromosomes of living human 
beings.”73  Judge Bryson concluded that “[o]ur role is to interpret the law 
that Congress has written in accordance with the governing precedents” 
and that “[t]here is no collective right of adverse possession to intellectual 
property, and we should not create one.”74  Given that Judge Bryson 
would affirm the district court’s rulings as to the BRCA gene and BRCA 
gene segment claims, which ruled that DNA is patent ineligible subject 
matter, these divergent positions set the stage for a subsequent appeal to 
the Supreme Court.75 
In the most recent iteration of Myriad, the Supreme Court addressed 
the question of whether Myriad’s patents and claims to isolated BRCA1 
and BRCA2 genes gave Myriad the exclusive right to isolate an 
individual’s BRCA genes.76  The Court held that “separating [a] gene 
 
68 Ass’n for Molecular Pathology, 689 F.3d at 1337. 
69 Id. at 1341. 
70 Id. at 1343. 
71 Id. at 1355. 
72 Id. at 1348. 
73 Id. at 1350. 
74 Ass’n for Molecular Pathology, 689 F.3d at 1350, 1358.  
75 Id.; Auth, supra note 54. 
76 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2116 (2013).   
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from its surrounding genetic material is not an act of invention,” and that 
genes isolated from human DNA claimed in Myriad’s patents were not 
patentable because the “location and order” of the molecules in those 
genes “existed in nature before Myriad found them” even though the 
process of isolating nucleic acids, the building blocks of DNA, involves 
changing their structure by breaking chemical bonds.77  Now, isolated 
genomic DNA is classified as a patent ineligible product of nature under 
35 U.S.C. § 101.78  However, cDNA is still patent-eligible because it is 
not naturally occurring.79  The Supreme Court’s holding therefore upheld 
the patentability of cDNA, but reversed the Federal Circuit’s 
determination of the patentability of isolated DNA.80 
For the first time, the Court made it exceedingly clear that Myriad’s 
mere discovery of the precise location and genetic sequence of BRCA1 
and BRCA2 within chromosomes 17 and 13 did not amount to a 
patentable invention.81  Myriad nonetheless maintained its claims to 
cDNA despite losing five of its 520 patent claims to BRCA1 and BRCA2 
DNA, including the three claims previously discussed.82  The Court 
agreed that cDNA is patent-eligible because cDNA is synthesized in such 
a way that it is non-naturally occurring and is not simply isolated.83  Thus, 
cDNA evaded the law of nature exception to patent eligibility.84 
Through Myriad, the Supreme Court clarified that it will not eagerly 
defer to existing patent law practice and that it may render opinions 
contrary to the desires of the USPTO or even the Federal Circuit.85  As an 
example, when considering the patent eligibility of a small molecule or 
protein isolated or purified from a natural source, the latest edition of the 
USPTO’s MPEP instructs that “[p]urer forms of known products may be 
patentable” and that “[p]ure materials are novel vis-à-vis less pure or 
 
77 Id.; see Brian Resnick, Why is Myriad Genetics Still Filing Patent Suits for Breast-
Cancer Tests?, NAT’L  J. (Aug. 8, 2013), http://www.nationaljournal.com/healthcare/why-is-
myriad-genetics-still-filing-patent-suits-for-breast-cancer-tests-20130808. 
78 Auth, supra note 54. 
79 Myriad Genetics, Inc., 133 S. Ct. at 2107, 2109. 
80 Resnick, supra note 77. 
81 Dayrel S. Sewell, Unanimous U.S. Supreme Court and Angelina Jolie: BRCA1 & 
BRCA2 Patentability, INTELL. PROP. TODAY 24 (July 2013). 
82 Id. 
83 Id. 
84 Id.  
85 Samuel B. Adams & Carl A. Morales, Myriad’s Possible Impact on Patent Eligibility 
of Isolated non-DNA Chemical Substances (June 19, 2013), 
http://www.lexology.com/library/detail.aspx?g=bdf4bfc3-2349-4c4d-bd23-d1d80d1467f0. 
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impure materials because there is a difference between pure and impure 
materials,” suggesting purified substances from natural sources may be 
patent-eligible.86  To the extent these guidelines support patentability of a 
small molecule or protein isolated or purified from a natural source, and 
to the extent that the USPTO has previously granted claims to such 
substances, Myriad suggests that these current and past practices by the 
agency may not be entitled to deference.87 
Just hours after the Myriad decision was released, the USPTO 
circulated a memorandum to all patent examiners.88  The memorandum 
advised that, “[e]xaminers should now reject product claims drawn solely 
to naturally occurring nucleic acids or fragments thereof, whether isolated 
or not, as being ineligible subject matter under 35 U.S.C. § 101.”89  
Although that particular piece of guidance is directly in line with the 
Myriad decision, a later sentence highlights uncertainty for the future as 
the guidelines recite, “[o]ther claims, including method claims, that 
involve naturally occurring nucleic acids may give rise to eligibility 
issues and should be examined under the existing guidance in Manual of 
Patent Examining Procedure (“MPEP”) 2106, Patent Subject Matter 
Eligibility.”90  “Method” claims are another word for “process” claims, 
and the USPTO’s statement here concerns patent practitioners and 
research institutions because the memorandum mentioned possible 
eligibility issues for method claims, despite the fact that the Myriad 
holding was expressly limited to non-method claims.91  With this 
dichotomy, the USPTO memorandum concludes by stating “[t]he 
USPTO is closely reviewing the decision in Myriad and will issue more 
comprehensive guidance on patent subject matter eligibility 
determinations, including the role isolation plays in those 
determinations.”92  On March 4, 2014, the USPTO issued its first guidance 
on this issue since Myriad, and issued additional, revised guidance on 
December 16, 2014.93 
 
86 Id. 
87 Id. 
88 Memorandum from Andrew H. Hirshfeld, Deputy Commissioner for Patent 
Examination Policy, for Patent Examining Corps (June 13, 2013), available at 
http://www.uspto.gov/patents/law/exam/myriad_20130613.pdf. 
89 Id. 
90 Id. (emphasis added). 
91 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2119 (2013). 
92 Memorandum from Andrew H. Hirshfeld (June 13, 2013), supra note 88. 
93 2014 Interim Guidance on Patent Subject Matter Eligibility, 79 Fed. Reg. 74618, 74619 
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B. USPTO Guidance—March 4, 2014 
In light of Myriad, the USPTO issued guidance for all claims 
reciting or involving laws of nature, natural principles, natural 
phenomena, and/or natural products.94  Notably, like all USPTO 
memoranda, this is not binding law and either the legislature can enact 
superseding statutes or courts can issue overriding opinions.95  The 
USPTO expressly stated that “while the holding in Myriad was limited to 
nucleic acids, Myriad is a reminder that claims reciting or involving 
natural products should be examined for a marked difference under 
Chakrabarty.”96  To do so, examiners should refer to the following 
flowchart:97 
98 
 
(Dec. 16, 2014), available at http://www.gpo.gov/fdsys/pkg/FR-2014-12-16/pdf/2014-
29414.pdf [hereinafter 2014 Interim Guidance]; Memorandum from Andrew H. Hirshfeld 
(June 13, 2013), supra note 88. 
94 Memorandum from Andrew H. Hirshfeld (Mar. 4, 2014), supra note 8. 
95 See, e.g., Myriad Genetics, Inc., 133 S. Ct. at 2107. 
96 Memorandum from Andrew H. Hirshfeld (Mar. 4, 2014), supra note 8. 
97 Id. 
 98  Id. at 3. 
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This chart illustrates a streamlined patent examination procedure by 
clearly defining what does and does not qualify as patent-eligible subject 
matter.99  It is no longer a subjective test with an open standard, but rather 
an objective one that follows a precise analysis, even with weighing 
twelve factors for ascertaining whether something is significantly 
different than a judicial exception.100  Interestingly, but perhaps 
unsurprisingly, the USPTO did not create this protocol, and in fact it 
appears that this analytical framework was derived from Judge Robert W. 
Sweet from the Southern District of New York.101  In the first opinion on 
the merits in the Myriad case-line, Judge Sweet held that fifteen of 
Myriad’s claims spanning seven patents were invalid under 35 U.S.C. § 
101, and issued a declaratory judgment against Myriad.102  Judge Sweet’s 
analysis of the claims followed the above structure.103 
Because the isolated DNA molecules were considered a 
composition of matter, and fell under the judicial exceptions as a product 
of nature, Judge Sweet analyzed whether the isolated DNA was markedly 
different from native DNA.104  Judge Sweet opined that the isolated DNA 
was not markedly different from native DNA, and could not be markedly 
different because of the very nature of DNA.105  The claims to isolated 
BRCA1 and BRCA2 DNA, in order to serve any importance for genetic 
testing, must maintain the “defining characteristic of DNA in its native . 
. . form [and this] mandates the conclusion that the challenged 
composition claims are directed to unpatentable products of nature.”106 
To summarize the flowchart, the first question asks whether a 
claimed invention is directed to patentable subject matter under 35 U.S.C. 
§ 101, and if it is not, then it cannot be patentable.107  The second question 
asks if there is a judicial exception, and if not, then the subject matter is 
patent eligible.108  The third question asks if the claim is significantly 
different from an unpatentable judicial exception, and thus qualifies as 
 
99 See id. at 3–4. 
100 Id. at 4–5. 
101 See Ass’n for Molecular Pathology v. USPTO, 702 F. Supp. 2d 181 (S.D.N.Y. 2010). 
102 Id. at 211. 
103 Id. at 227–28. 
104 Id.  
105 Id. at 229. 
106 Id. 
107 Memorandum from Andrew H. Hirshfeld (Mar. 4, 2014), supra note 8, at 2. 
108 Id. at 3. 
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patent-eligible subject matter.109  To analyze whether a claimed invention 
is significantly different, there are six factors that weigh in favor of 
eligibility and six factors that weigh against eligibility.110 
Factors that weigh toward eligibility (significantly different): 
 
a) Claim is a product claim reciting something that initially appears to be a natural 
product, but after analysis is determined to be non-naturally occurring and 
markedly different in structure from naturally occurring products. 
b) Claim recites elements/steps in addition to the judicial exception(s) that impose 
meaningful limits on claim scope, i.e., the elements/steps narrow the scope of the 
claim so that others are not substantially foreclosed from using the judicial 
exception(s). 
c) Claim recites elements/steps in addition to the judicial exception(s) that relate 
to the judicial exception in a significant way, i.e., the elements/steps are more 
than nominally, insignificantly, or tangentially related to the judicial exception(s). 
d) Claim recites elements/steps in addition to the judicial exception(s) that do 
more than describe the judicial exception(s) with general instructions to apply or 
use the judicial exception(s). 
e) Claim recites elements/steps in addition to the judicial exception(s) that include 
a particular machine or transformation of a particular article, where the particular 
machine/transformation implements one or more judicial exception(s) or 
integrates the judicial exception(s) into a particular practical application. (See 
MPEP 2106(II)(B)(1) for an explanation of the machine or transformation 
factors). 
f)Claim recites one or more elements/steps in addition to the judicial exception(s) 
that add a feature that is more than well-understood, purely conventional or 
routine in the relevant field. 
 
Factors that weigh against eligibility (not significantly different): 
 
g) Claim is a product claim reciting something that appears to be a natural product 
that is not markedly different in structure from naturally occurring products. 
h) Claim recites elements/steps in addition to the judicial exception(s) at a high 
level of generality such that substantially all practical applications of the judicial 
exception(s) are covered. 
i)Claim recites elements/steps in addition to the judicial exception(s) that must be 
used/taken by others to apply the judicial exception(s). 
j)Claim recites elements/steps in addition to the judicial exception(s) that are 
well-understood, purely conventional or routine in the relevant field.  
k) Claim recites elements/steps in addition to the judicial exception(s) that are 
insignificant extra-solution activity, e.g., are merely appended to the judicial 
exception(s). 
l)Claim recites elements/steps in addition to the judicial exception(s) that amount 
to nothing more than a mere field of use.111  
 
 
 
109 Id. at 3. 
110 Id. at 4–5. 
111 Id. 
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For practical purposes, the USPTO also provides several examples of the 
steps examiners should take and conclusions they should reach when 
analyzing claim eligibility.
112
 
Not surprisingly, the multi-factor test compliments the Myriad 
decision.  One factor weighing against eligibility is whether the “[c]laim 
is a product claim reciting something that appears to be a natural product 
that is not markedly different in structure from naturally occurring 
products.”
113
  Under this analysis, isolated DNA is not patentable because 
it is not markedly different from the chromosomal DNA, as both forms 
of DNA have identical nucleotide sequences.
114
  Although there is a 
resulting difference in the molecule’s structure, that difference does not 
rise to the level of a marked difference.
115
  Here, the analysis of cDNA 
under the twelve eligibility factors is of utmost importance.  Even though 
the process of making cDNA may very well be routine in the 
biotechnology art, the USPTO reasons that cDNA nonetheless has a 
nucleotide sequence markedly different from naturally occurring DNA 
and is therefore patent-eligible subject matter.
116
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
112 Id. at 11–13.  
113 Memorandum from Andrew H. Hirshfeld (Mar. 4, 2014), supra note 8, at 4. 
114 Id. at 5. 
115 Id. 
116 Id. at 5. 
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C. USPTO Guidance—December 16, 2014 
In response to public feedback from the USPTO’s March 2014 
guidance, the USPTO issued renewed guidance on December 16, 2014.
117
  
This renewed guidance includes a new flowchart examiners should 
follow when assessing patentability claims: 
118
 
 
 
 
 
117 Austin Donohue, USPTO Issues New Myriad Guidance, BIOTECHNOW (Dec. 17, 
2014), http://www.biotech-now.org/public-policy/patently-biotech/2014/12/uspto-issues-
new-myriad-guidance#; see 2014 Interim Guidance, supra note 93, at 74618. 
118 2014 Interim Guidance, supra note 93, at 74621. 
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As the USPTO points out, there are two notable changes between this 
flowchart and the previous flowchart: 
• All claims (product and process) with a judicial exception (any type) are subject 
to the same steps. 
• Claims including a nature-based product are analyzed in Step 2A to identify 
whether the claim is directed to (recites) a “product of nature” exception.  This 
analysis compares the nature-based product in the claim to its naturally occurring 
counterpart to identify markedly different characteristics based on structure, 
function, and/or properties.  The analysis proceeds to Step 2B only when the 
claim is directed to an exception (when no markedly different characteristics are 
shown).119 
In other words, the test now inquires in Step 2B as to whether the 
additional elements amount to “significantly more” than a judicial 
exception as opposed to the prior language of the claim as a whole 
reciting something “significantly different” than the judicial exception.
120
  
While Step 2A appears to remain unchanged textually, an examiner 
should apply it to nature-based products by determining whether a nature-
based product limitation in a claim needs to be evaluated using a 
markedly different characteristic analysis, and performing that analysis if 
necessary.
121
  “This revised analysis represents a change from prior 
guidance, because now changes in functional characteristics and other 
non-structural properties can evidence markedly different characteristics, 
whereas in the [March 2014 guidance] only structural changes were 
sufficient to show a marked difference.”
122
  Importantly, 
a product that is purified or isolated, for example, will be eligible when there is a 
resultant change in characteristics sufficient to show a marked difference from 
the product’s naturally occurring counterpart.  If the claim recites a nature-based 
product limitation that does not exhibit markedly different characteristics, the 
claim is directed to a “product of nature” exception (a law of nature or naturally 
occurring phenomenon), and the claim will require further analysis to determine 
eligibility based on whether additional elements add significantly more to the 
exception.123 
From a patentability standpoint, although inquiring “whether additional 
elements add significantly more to the exception” is a positive 
development that will likely maintain the patentability of genetic tests, “it 
 
119 Compare id., with Memorandum from Andrew H. Hirshfeld (Mar. 4, 2014), supra 
note 8, at 2. 
120 Compare 2014 Interim Guidance, supra note 93, with Memorandum from Andrew H. 
Hirshfeld (Mar. 4, 2014), supra note 8, at 2. 
121 Donald Zuhn, USPTO Issues Interim Guidance on Subject Matter Eligibility, PATENT 
DOCS (Dec. 16, 2014), http://www.patentdocs.org/2014/12/uspto-issues-interim-guidance-
on-subject-matter-eligibility.html. 
122 2014 Interim Guidance, supra note 93, at 74623 n.27. 
123 Id. 
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will be a long time before we see more stability in this area of patent 
law.”
124
  Just one day after issuing this guidance, the Court of Appeals for 
the Federal Circuit issued another decision in the Myriad line, discussed 
below.
125
 
 
D. Myriad at Present and the Uncertain Future 
Shortly after the Supreme Court decision, Myriad fired back and 
filed infringement suits against its competitors.  Initially, Myriad filed 
lawsuits against Ambry Genetics Corp. and Gene By Gene Ltd., who 
began offering BRCA1 and BRCA2 tests for $2,280 and $995 
respectively, a price cheaper than the $4,300 Myriad charges.
126
  Since 
those two suits, Myriad also sued BioReference Laboratories, Inc. 
(“BioReference”) in Utah federal court alleging that BioReference, 
through its genetic sequencing laboratory subsidiary, GeneDx, Inc., 
infringed Myriad’s intellectual property by offering OncoGeneDx, a 
comprehensive series of inherited cancer carrier testing, which includes 
testing for BRCA1 and BRCA2.
127
  Myriad later sued Invitae claiming 
infringement of claims in eleven patents underlying Myriad’s 
BRACAnalysis test for hereditary breast and ovarian cancer risk.
128
  In 
response, Invitae countersued for a declaratory judgment of non-
infringement.
129
  Additionally, Quest Diagnostics (“Quest”) sought a 
declaratory judgment that it would not be infringing on Myriad’s patents 
by selling tests for the BRCA genes; two weeks later Myriad filed suit 
against Quest, too.
130
  Further, a sixth entity, Counsyl, is currently seeking 
 
124 Id. at 74623; Donohue, supra note 117. 
125 BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. v. Ambry Genetics 
Corp., 2014 U.S. App. LEXIS 23692, at *1 (Fed. Cir. Dec. 17, 2014). 
126 Resnick, supra note 77. 
127 BioReference Laboratories, Inc. Sued by Myriad Genetics, Confident in Its Position, 
GLOBENEWSWIRE (Oct. 22, 2013), http://globenewswire.com/news-
release/2013/10/22/582274/10053651/en/BioReference-Laboratories-Inc-Sued-by-Myriad-
Genetics-Confident-in-Its-Position.html. 
128 InVitae Countersues Myriad in Northern California District Court, GENOMEWEB 
(Dec. 2, 2013), http://www.genomeweb.com/clinical-genomics/invitae-countersues-myriad-
northern-california-district-court. 
129 Id. 
130 BioReference Laboratories, Inc. Sued by Myriad Genetics, Confident in its Position: 
Company Not Yet Served, but has Been Prepared for an Expected Action, MARKETWATCH 
(Oct. 22, 2013, 8:13 AM), http://www.marketwatch.com/story/bioreference-laboratories-inc-
sued-by-myriad-genetics-confident-in-its-position-2013-10-22?reflink=MW_news_stmp; 
Myriad Sues Quest Over BRCA1/2 Patents, GENOMEWEB (Oct. 24, 2013), 
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a declaratory judgment, similar to Quest, that it is not infringing Myriad’s 
patents.
131
  To date, only Ambry and Gene By Gene countersued Myriad 
for antitrust violations.
132
  However, Myriad and Gene By Gene have 
since settled their disputes.
133
  As part of the settlement terms, Gene By 
Gene cannot sell its genetic test for BRCA1 and BRCA2 alone, but can 
continue to sell its array that tests multiple genes including BRCA1 and 
BRCA2.
134
 
Fundamentally, Myriad executives believe that the company 
possesses valid patent claims covering what they consider a new 
biomarker, new reagents and techniques for analyzing the biomarker, and 
new methods for determining a patient’s risk of breast and ovarian cancer 
using these reagents and techniques.
135
  Myriad argues that the 515 valid 
claims it still holds relating to the BRCA1 and BRCA2 tests are sufficient 
for the issuance of the preliminary injunctions it is seeking against its 
competitors.
136
  To recapitulate, the Supreme Court holding in Myriad 
only invalidated five of Myriad’s original 520 claims spanning the many 
patents it holds on BRCA1 and BRCA2 genetic testing.
137
 
Despite the fact that Myriad maintains it still holds 515 valid and 
enforceable claims in twenty-four patents, its competitors are clearly 
fighting back.  A spokesperson from Quest stated that the company 
expected Myriad’s lawsuit and described it as “merely the latest in a 
 
http://www.genomeweb.com/clinical-genomics/myriad-sues-quest-over-brca12-patents. 
131 Counsyl Files for Declaratory Judgment That It’s Not Infringing Myriad’s BRCA 
Patent Claims, GENOMEWEB (Sept. 27, 2013), http://www.genomeweb.com/clinical-
genomics/counsyl-files-declaratory-judgment-its-not-infringing-myriads-brca-patent-claims. 
132 Brief for Defendant, Univ. of Utah Research Found. v. Ambry Genetics Corp., No. 
2:13-cv-00640-RJS (In re BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig.), 
3 F. Supp. 3d 1213 (D. Utah 2014), available at http://cdn.arstechnica.net/wp-
content/uploads/2013/08/Ambry-Myriad-Antitrust-docs1.pdf; Gene by Gene Joins Ambry in 
Countersuit against Myriad Alleging Antitrust Violations, GENOMEWEB (Aug. 15, 2013), 
https://www.genomeweb.com/sequencing/gene-gene-joins-ambry-countersuit-against-
myriad-alleging-antitrust-violations. 
133 BRCA Patent Owners and Gene by Gene, Ltd. Resolve Patent Suit, MYRIAD (Feb. 7, 
2013), http://investor.myriad.com/releasedetail.cfm?ReleaseID=824154. 
134 Id. 
135 Resnick, supra note 77. 
136 Brief for Plaintiff, Univ. of Utah Research Found. v. Ambry Genetics Corp., No. 2:13-
cv-00640-RJS (In re BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig.), 3 F. 
Supp. 3d 1213 (D. Utah 2014), available at 
http://ia601800.us.archive.org/24/items/gov.uscourts.utd.89779/gov.uscourts.utd.89779.5.0.
pdf [hereinafter Brief for Plaintiff Ambry]. 
137 Id. 
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pattern of behavior toward any test provider that introduces a new option 
in BRCA testing that can benefit patients.”
138
  Quest is apparently 
confident that its genetic test does not violate any of Myriad’s claims and 
plans to vigorously defend its product.
139
  Similarly, Invitae asserts that 
its genetic test is not covered by any valid claim of a Myriad patent.
140
  
Invitae also alleges that its comprehensive test offers the sequencing of 
over 200 human genes for less than the single Myriad BRCA1/2 test.
141
  
Even more dramatic, Invitae alleges that approximately fifty additional 
claims in four of Myriad’s patents should be invalidated because they are 
invalid method claims.
142
  Time will tell which party is indeed correct, and 
on what precise grounds.  A court’s finding of either infringement or non-
infringement necessarily implies a straightforward winner and loser, 
unlike the ruling in Myriad where the Supreme Court invalidated just five 
claims spanning all of Myriad’s patents, and did not completely divest 
Myriad of its patent exclusivity.
143
  Absent a settlement, one party must 
prevail, and the future of the genetic testing industry might be forever 
changed.  A defeat for Myriad could devastate the industry for many 
reasons, one of which is rooted in the AIA and discussed below.  But 
now, the latest authority on this matter is the Court of Appeals for the 
Federal Circuit’s opinion in Ambry.
144
 
Myriad appealed the District Court of Utah’s March 10, 2014 
decision denying Myriad’s request for preliminary injunction to halt 
Ambry’s sale of BRCA1 and BRCA2 genetic tests.
145
  The District 
 
138 Myriad Sues Quest Over BRCA1/2 Patents, supra note 130. 
139 InVitae Countersues Myriad in Northern California District Court, GENOMEWEB, 
supra note 130. 
140 Brief for Plaintiff Ambry, supra note 136 (citing Myriad Patent No. 6,033,857, claim 
4) (requiring “(e) amplifying all or part of the BRCA2 gene from said tissue sample using 
primers for a specific BRCA2 mutant allele” when Invitae’s tests do not use any such DNA 
primers). 
141 Complaint at 2, Invitae Corp. v. Myriad Genetics, Inc., No. 3:13-cv-05495-1 (N.D. 
Cal. 2013), available at http://patentdocs.typepad.com/files/cand-3-13-cv-05495-1.pdf. 
142 Id. see, e.g., claims 2, 3, 5, 8, 13–15, 17–20, 23, 30, and 33 of U.S. Patent No. 
5,753,441; claims 3–8 of U.S. Patent No. 6,033,857; claims 32, 33, and 44 of U.S. Patent No. 
6,051,379; and claims 1–18 of U.S. Patent No. 6,951,721.  Invitae based its allegations on the 
Federal Circuit’s holding that was neither appealed to nor decided by the Supreme Court.   
143 See Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2119 
(2013). 
144 BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. v. Ambry Genetics 
Corp., 2014 U.S. App. LEXIS 23692, at *1 (Fed. Cir. Dec. 17, 2014). 
145 Univ. of Utah Research Found. v. Ambry Genetics Corp. (In re BRCA1- & BRCA2-
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Court’s ruling was affirmed on appeal because the claims at issue were 
directed to invalid subject matter.
146
  Myriad asserted six claims spanning 
three patents and importantly included two that involved screening 
patients covering the method of performing a genetic test.
147
  The court 
first found that parts of those two claims were invalid because they were 
directed to the patent-ineligible abstract idea of comparing BRCA 
sequences.
148
 
Turning to the remaining parts of those claims, the court found that 
the “non-patent-ineligible elements do not add ‘enough’ to make the 
claims as a whole patent-eligible.”
149
  In so finding, the court reasoned the 
claimed elements “set forth well-understood, routine, and conventional 
activity engaged in by scientists at the time of Myriad’s patent 
applications.”
150
  Simply put, the non-patent-ineligible elements of the 
two claims did nothing more than spell out what practitioners already 
knew, which was how to compare gene sequences using routine, ordinary 
techniques.
151
  However, the court left open the possibility that Myriad 
could have been successful if it instead sought an injunction on one of its 
claims that was directed towards a method of detecting alterations where 
the alterations were specifically the genetic mutations that Myriad 
discovered.
152
  With the overall patentability of genetic tests still at issue, 
the focus now shifts to the ways in which patents can be challenged by 
means other than lawsuits in federal courts. 
 
IV.  POST-GRANT PROCEEDINGS 
A. Overview of the AIA’s New Post-Grant Proceedings 
There are several ways third parties can persuade the USPTO to 
cancel others’ patents or claims.  It is certainly advantageous to contest 
patents in the USPTO, as opposed to the federal courts, and even more so 
after the AIA.  Before the AIA, patent cancellation options available to 
 
Based Hereditary Cancer Test Patent Litig.), 3 F. Supp. 3d 1213, 1277 (D. Utah 2014). 
146 BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig., 2014 U.S. App. 
LEXIS 23692, at *1. 
147 Id. at *11–13. 
148 Id. at *16–17. 
149 Id. at *20. 
150 Id. 
151 Id. 
152 BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig., 2014 U.S. App. 
LEXIS 23692, at *21–22. 
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third parties through the USPTO included: (1) third party prior art 
submissions; (2) ex parte reexamination; and (3) inter partes 
reexamination.
153
  Third party prior art submissions allowed for third 
parties to submit patents, published patent applications, or printed 
publications that may have been relevant to the examination of a patent 
application.
154
  Ex parte reexamination allowed for third parties to 
challenge any unexpired patents on the basis of novelty, obviousness, and 
claim scope.
155
  Such challenges were successful upon finding a 
substantial new question of patentability.
156
  Inter partes reexamination 
was very similar to ex parte reexamination, but was a more extensive and 
costly proceeding whereby the petitioner prevailed upon proving a 
reasonable likelihood of success as to at least one claim, a much lower 
burden required for raising a substantial new question of patentability.
157
  
However, the patent community criticized those options.
158
  Third party 
prior art submissions were simply inadequate, ex parte reexamination was 
too narrow in scope and too lengthy in pendency, and inter partes 
reexamination was viewed as too risky in light of its estoppel 
provisions.
159
  Also, under the old provisions, there were growing 
concerns about using the judicial system to resolve patent disputes in the 
United States, including, but not limited to: cost, nearly unlimited 
discovery, lay juries, and lengthy pendency.
160
 
The rollout of the AIA drastically changed these patent cancellation 
options.  First, third party prior art submissions, now known as pre-
issuance submissions, have been adapted to better provide patent 
 
153 See Prior Art Citations to Office and Ex Parte Reexamination of Patents, 35 U.S.C. §§ 
301–07 (2012); Inter Partes Review, 35 U.S.C. §§ 311–19 (2012). 
154 Gene Quinn, AIA Oddities: Third Party Submissions of Prior Art, IPWATCHDOG 
(Sept. 19, 2013, 8:25 AM), http://www.ipwatchdog.com/2013/09/19/aia-oddities-third-party-
submissions-of-prior-art/id=45118/; Preissuance Submissions, USPTO, 
http://www.uspto.gov/aia_implementation/faqs-preissuance-submissions.jsp (last visited 
Apr. 19, 2014); see 35 U.S.C. § 122(e) (2012); 37 CFR § 1.290 (2014). 
155 Comparison of Post-Grant Proceedings, RATNER PRESTIA, 
http://www.rppostgrant.com/ComparisonCharts/post-grant-review-comparison.html (last 
visited Apr. 19, 2014). 
156 Id. 
157 Id. 
158 See Filipe De Corte, et al., AIA Post-Grant Review and European Oppositions: Will 
They Work in Tandem, or Rather Pass Like Ships in the Night?, 14 N.C. J.L. & TECH. 93 
(2012). 
159 Id. at 96. 
160 Quinn, supra note 154. 
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examiners with the best possible prior art references.
161
  Pre-issuance 
submissions allow for third parties to accompany their submissions of 
patents, published patent applications, or printed publications with a 
concise written description of the relevance of those documents.
162
  
Second, ex parte reexamination, renamed post-grant review (“PGR”), is 
fundamentally still in place and is instituted under the same general 
standard of review.
163
  But, there are some key changes that make PGR 
better adapted to serve as a quasi-judicial administrative proceeding to 
help relieve some of the burden of patent litigation from domestic federal 
courts.
164
  Third, inter partes reexamination has been replaced by inter 
partes review (“IPR”).
165
  Although IPR’s standard of review is 
unchanged, IPR can only be initiated on the basis of novelty and 
nonobviousness concerns, as opposed to enablement and arguably even 
patentability under 35 U.S.C. § 101, which can be raised in PGR.
166
  Both 
IPR and PGR are statutorily designed to be resolved within one year of 
their institution, as opposed to the pre-AIA proceedings that would last 
two to three years.
167
 
Though estoppel applies to the petitioner in an IPR, only that entity 
cannot request or maintain a subsequent proceeding before USPTO with 
respect to any challenged patent claim on any ground that was raised or 
reasonably could have been raised.
168
  This leaves open the door for other 
third parties to initiate a subsequent IPR.
169
  Likewise, the petitioner may 
not assert in a subsequent action that a claim is invalid on any ground that 
was raised or reasonably could have been raised in the IPR.
170
  Again, that 
 
161 Proposed New Rules Under AIA to Affect Third-Party Submissions of Prior Art, 
BRINKS, GILSON & LIONE (May 31, 2012), http://www.brinksgilson.com/news_events/3406-
proposed-new-rules-under-aia-affect-third-party-submissions-prior-art. 
162 Quinn, supra note 154. 
163 Id. 
164 Id. 
165 Post-Grant: Inter Partes Review, FISH & RICHARDSON, http://fishpostgrant.com/inter-
partes-review/ (last visited Mar. 22, 2014). 
166 Id. 
167 Comparison of Post-Grant Proceedings, supra note 155. 
168 America Invents Act (AIA) Frequently Asked Questions, USPTO, 
http://www.uspto.gov/patent/laws-and-regulations/america-invents-act-aia/america-invents-
act-aia-frequently-asked (last visited May 13, 2015). 
169 Id. 
170 Id. 
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provision only impacts the original petitioner.
171
  These provisions are the 
extent of estoppel, and invalidity opinions will absolutely not carry over 
between patents.  So at least in theory, it is more efficient for a single 
court to rule on the invalidity of entire classes of patents than for the 
USPTO to issue opinions through post-grant proceedings that 
collectively accomplish the same result; thus, it is necessary for the courts 
to subsequently decide Myriad’s unsettled litigation.
172
  The focus now 
turns to the precise effects that unsettled litigation will have on both PGR 
and IPR. 
 
B. PGR 
Congressional hearings between 2001 and 2006 explored the 
creation of PGR proceedings where patents are challenged early in life 
and on all validity grounds.
173
  Such a request was called for by the core 
intellectual property professional organizations and accompanying 
reports and studies.
174
  At a 2004 House Intellectual Property 
Subcommittee hearing, the American Intellectual Property Law 
Association (“AIPLA”) Executive Director, Michael Kirk, argued to 
authorize post-grant review.
175
  He believed that testing the validity of a 
newly issued patent that is of dubious validity is often prohibitively 
expensive or impossible, and the continued existence of such a patent can 
 
171 Id. 
172 Id. 
173 See generally Perspectives on Patents: Post-Grant Review Procedures and other 
Litigation Reforms: Hearing Before the Subcomm. on Intellectual Prop. of the S. Comm. on 
the Judiciary, 109th Cong. (2006); Patent Quality Improvement: Post-Grant Opposition: 
Hearing Before the Subcomm. on Courts, the Internet, and Intellectual Prop. of the H. Comm. 
on the Judiciary, 108th Cong. (2004) [hereinafter 2004 House hearing]; Patent 
Reexamination and Small Business Innovation: Hearing Before the Subcomm. on Courts, the 
Internet, and Intellectual Prop. of the H. Comm. on the Judiciary, 107th Cong. (2002); 
Patents: Improving Quality and Curing Defects: Hearing Before the Subcomm. on Courts, 
the Internet, and Intellectual Prop. of the H. Comm. on the Judiciary, 107th Cong. (2001) 
[hereinafter 2001 House hearing]. 
174 See 2004 House hearing, supra note 173, at 13–16 (statement of James Toupin, 
General Counsel, USPTO), 38 (statement of Michael Kirk, Executive Director, AIPLA) (“The 
call for an effective, efficient post-grant system to review patents has reached a crescendo.  It 
is time to act.”), 52 (Letter of Biotechnology Industry Organization) (listing reports and 
groups).  For a history of the events leading to the enactment of inter partes reexamination in 
1999, see 2001 House hearing, supra note 173, at 38 (statement of Michael Kirk, Executive 
Director, AIPLA), 46 (statement of Jeffrey Kushan, Powell, Goldstein, Frazer, and Murphy). 
175 2004 House hearing, supra note 173, at 32 (statement of Michael Kirk, Executive 
Director, AIPLA). 
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disrupt product development in a field of technology for years.
176
  Invalid 
or overbroad patents both discourage follow-on innovation, preventing 
competition, and also raise prices through unnecessary licensing and 
litigation.
177
  Additionally, the “USPTO is a particularly appropriate 
venue for making validity determinations in a cost-effective and 
technically sophisticated environment.”
178
  It stands to reason that PGR 
serves a significant and substantial purpose.
179
 
Section 6 of the AIA amended Chapter 31’s authorization of inter 
partes proceedings and created the new PGR administrative 
proceedings.
180
  The law now allows the Director of the USPTO to 
institute PGR proceedings if he finds that the information presented in 
the petition and any response “[shows] that there is a reasonable 
likelihood that the petitioner would prevail with respect to at least one of 
the claims challenged in the petition.”
181
 
For petitions filed on or after March 19, 2013, PGR costs $12,000 
plus a $250.00 fee for each claim in excess of twenty within the patent; 
the post-institution fee is $18,000 plus a $550.00 fee for each claim in 
excess of fifteen within the patent.
182
  Thus, for $32,750, up to twenty 
claims in a single patent can be reviewed in PGR, with an additional cost 
of $800 per claim reviewed in excess of twenty.  Post-institution fees 
represent fees that are paid up front but refunded in the event that the 
petitioner’s request for PGR is denied.
183
 
The provision enacted for post-grant proceedings, 35 U.S.C. § 321, 
states in part: “[a] petitioner in a post-grant review may request to cancel 
 
176 Id. at 29 (statement of Michael Kirk, Executive Director, AIPLA). 
177 Evolving IP Marketplace: Aligning Patent Notice and Remedies with Competition, 
FTC.GOV (Mar. 2011), available at 
http://www.ftc.gov/sites/default/files/documents/reports/evolving-ip-marketplace-aligning-
patent-notice-and-remedies-competition-report-federal-trade/110307patentreport.pdf. 
178 Perspectives on Patents: Harmonization and Other Matters: Hearing Before the 
Subcomm. on Intellectual Prop. of the S. Comm. on the Judiciary, 109th Cong. 77 (2005) 
(statement of Q. Todd Dickinson, Vice President and Chief Intellectual Property Counsel, 
General Electric Co., and former USPTO Director). 
179 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2120 (2013).  
180 Leahy-Smith America Invents Act, § 314(a), Pub. L. No. 112–29, Sec. 6(a), 125 Stat. 
284, 300 (codified as amended in scattered sections of 35 U.S.C.). 
181 Id. 
182 America Invents Act (AIA) Frequently Asked Questions, supra note 168. 
183 Post-Grant Alert: New PTO Fees Effective March 19, 2013, FISH & RICHARDSON 
(Mar. 22, 2013), http://fishpostgrant.com/news/post-grant-alert-new-pto-fees-effective-
march-19-2013/. 
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as unpatentable [one] or more claims of a patent on any ground that could 
be raised under paragraph (2) or (3) of section 282(b) (relating to 
invalidity of the patent or any claim).”
184  Of particular relevance in the 
analysis is 35 U.S.C. § 321(b), which defines the grounds under 282(b).
185
  
35 U.S.C. § 282(b) states: 
(b) Defenses.— The following shall be defenses in any action involving the 
validity or infringement of a patent and shall be pleaded: 
(1) Noninfringement, absence of liability for infringement or unenforceability. 
(2) Invalidity of the patent or any claim in suit on any ground specified in part II 
as a condition for patentability. 
(3) Invalidity of the patent or any claim in suit for failure to comply with—
(A) any requirement of section 112, except that the failure to disclose the best 
mode shall not be a basis on which any claim of a patent may be canceled or held 
invalid or otherwise unenforceable; or (B) any requirement of section 251. 
(4) Any other fact or act made a defense by this title.186 
Limiting the analysis to the specified paragraphs (2) and (3), post-
grant proceedings can be brought up against patents for reasons including 
“condition[s] for patentability” or violations of 35 U.S.C. § 112 or § 
251.
187
  For the purpose of this discussion, the primary concern is defining 
the phrase “a condition for patentability.” 
In one prominent view, the Patent Act sets out the conditions for 
patentability in sections § 101, § 102, and § 103.
188
  Much additional 
precedent supports this notion.
189
  In the eyes of the USPTO leadership, 
commentators incorrectly state that 35 U.S.C. § 101 is not a condition for 
patentability and cannot be grounds for PGR because it is not expressly 
stated within the text of 35 U.S.C. § 282(b)(3).
190
  The USPTO leadership 
 
184 35 U.S.C. § 321 (2012). 
185 Id. 
186 Id. § 282(b). 
187 Id. 
188 See Graham v. John Deere Co. of Kan. City, 383 U.S. 1, 12 (1966) (“The [1952 Patent] 
Act sets out the conditions of patentability in three sections.  An analysis of the structure of 
these three sections indicates that patentability is dependent upon three explicit conditions: 
novelty and utility as articulated and defined in § 101 and § 102, and nonobviousness, the new 
statutory formulation, as set out in § 103.”). 
189 See Aristocrat Techs. Austl. Pty Ltd. v. Int’l Game Tech., 543 F.3d 657, 661 (Fed. Cir. 
2008).  In addition to allowing for post-grant review under 35 U.S.C. § 112, section 282(b) 
also allows for post-grant review on any ground specified in title 35 as “a condition for 
patentability.”  Id.  While 35 U.S.C. §§ 102 and 103 are expressly titled “conditions for 
patentability,” 35 U.S.C. § 101 is generally also considered to be a condition for patentability, 
and thus appears to be a ground under which a petitioner can assert invalidity in a post-grant 
review.  Id. 
190 David Kappos, PTAB and Patentability Challenges, DIRECTOR’S FORUM: A BLOG 
FROM USPTO’S LEADERSHIP (Sept. 24, 2012, 4:44 PM), 
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further opines that commentators incorrectly assert that because 35 
U.S.C. § 101 is not included in § 282(b)(2), it is not “specified in part II 
as a condition for patentability” although § 101 is entitled “[i]nventions 
patentable,” unlike § 102 and § 103 that are both entitled “[c]onditions 
for patentability.”
191
  This assertion is made even though § 101 is included 
“in part II” of Title 35.
192
  However, the USPTO leadership does not find 
that argument persuasive and believes that for the purpose of PGR, 35 
U.S.C. § 101 is considered a condition for patentability.
193
 
The Supreme Court previously held that 35 U.S.C. § 101 is a 
condition for patentability.
194
  In Graham v. John Deere Co. of Kansas 
City,
195
 the Supreme Court stated in dicta that the 1952 Patent Act “sets 
out the conditions of patentability in three sections,” citing 35 U.S.C. § 
101, § 102, and § 103.
196
  The Supreme Court also addressed invalidity 
under 35 U.S.C. § 101 when it was raised as a defense to an infringement 
claim under 35 U.S.C. § 282.
197
 
Additionally, the Federal Circuit expressly rejected the argument 
raised by the dissent in Dealertrack, Inc. v. Huber
198
 that 35 U.S.C. § 101 
is not a “condition for patentability” under 35 U.S.C. § 282, stating that 
“the defenses provided in the statute, 35 U.S.C. § 282, include not only 
the conditions of patentability in 35 U.S.C. §§ 102 and 103, but also those 
in 35 U.S.C. § 101.”
199
  The Federal Circuit in Dealertrack clarified that 
the use of the phrase “conditions for patentability” in the titles of 35 
U.S.C. §§ 102 and 103, but not 35 U.S.C. § 101, did not change the result; 
here, the court relied on the Supreme Court’s pronouncement in 
Pennsylvania Department of Corrections v. Yeskey,
200
 that a statute’s title 
“is of use only when it sheds light on some ambiguous word or phrase” 
 
http://www.uspto.gov/blog/director/entry/ptab_and_patentability_challenges. 
191 Id. 
192 Id. 
193 Id. 
194 See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1305 
(2012); Graham v. John Deere Co. of Kan. City, 383 U.S. 1, 12 (1966). 
195 Graham, 383 U.S. at 12. 
196 Id. 
197 Mayo, 132 S. Ct. at 1305. 
198 Dealertrack v. Huber, 674 F.3d 1315, 1330 n.3 (Fed. Cir. 2012) (Plager, J., dissenting). 
199 Id. (internal quotation marks omitted) (citing Aristocrat Tech. Austl. Pty Ltd. v. Int’l 
Game Tech., 543 F.3d 657, 661 (Fed. Cir. 2008)). 
200 Pa. Dep’t of Corrs. v. Yeskey, 524 U.S. 206, 212 (1998) (quoting Trainmen v. 
Baltimore & Ohio R.R. Co., 331 U.S. 519, 528–29 (1947)). 
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in the statute and that it “cannot limit the plain meaning of the text.”
201
  
In additional reflections by the now-retired Chief Judge Rader, he 
posited that the Supreme Court long ago held that 35 U.S.C. § 101 is not 
a “condition of patentability.”
202
  Chief Judge Rader acknowledged that 
the statute does not list 35 U.S.C. § 101 among the invalidity defenses to 
infringement, but instead under 35 U.S.C. § 282.
203
  As such, while 
invalidity for failing to meet a “condition of patentability” is among the 
authorized defenses, 35 U.S.C. § 101 is arguably not a “condition of 
patentability.”
204
 
Contrary to the views expressed by several judges of the Federal 
Circuit, the legislative history of the AIA makes it clear that Congress 
instituted the Patent Trial and Appeal Board (“PTAB”) to consider 
challenges brought under 35 U.S.C. § 101 in post-grant reviews.
205
  A 
House Committee Report provides that “the post-grant review 
proceeding permits a challenge on any ground related to invalidity under 
section 282.”
206
  Likewise, Arizona Senator Jon Kyl included “section 101 
invention issues” among those “that can be raised in post-grant review.”
207
  
To summarize, despite the opinions that 35 U.S.C § 101 is not a condition 
for patentability, in the view of the USPTO, the PTAB should consider 
patentability challenges brought under 35 U.S.C. § 101 in post-grant 
reviews.
208
  Unless the courts or Congress direct the USPTO otherwise, 
the USPTO will continue to do exactly that.
209
 
Such a conclusion implies that patents or patent claims can be 
canceled by a third party through the USPTO on 35 U.S.C. § 101 grounds 
for a fraction of the cost of litigation.
210
  A 2005 study found that 4,382 of 
the 23,688 human genes in the National Center for Biotechnology 
Information’s gene database are explicitly claimed as intellectual 
 
201 Trainmen v. Baltimore & Ohio R.R. Co., 331 U.S. at 528–29. 
202 CLS Bank Int’l v. Alice Corp. Pty, 717 F.3d 1269, 1335 (Fed. Cir. 2013) (citing 
Diamond v. Diehr, 450 U.S. 175, 189–90 (1981); In re Bergy, 596 F.2d 952, 963 (CCPA 
1979) (Section 101 “was never intended to be a ‘standard of patentability,’ the standards, or 
conditions as the statute calls them, are in 102 and 103”)). 
203 CLS Bank Int’l, 717 F.3d at 1335.  
204 Id. 
205 H.R. REP. NO. 112-98, at 47 (2011). 
206 Id. 
207 112 CONG. REC. S157, 1375 (daily ed. Mar. 8, 2011). 
208 Kappos, supra note 190. 
209 Id. 
210 Post-Grant Alert: New PTO Fees Effective March 19, 2013, supra note 183. 
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property.
211
  Patents with claims to those 4,382 genes will be safe from 
PGR because PGR can only be implemented on patents filed after March 
16, 2013.  However, future patents issued are now possibly at risk for 
being invalidated through PGR after Myriad.
212
  PGR could be instituted 
for a patent if the twelve factors examiners consider when reviewing 
patent applications under 35 U.S.C. § 101 demonstrate that it is “more 
likely than not that at least one claim is unpatentable.”
213
  Therefore, a 
third party showing that a greater number of factors weigh against 
patentability rather than for patentability is sufficient to invalidate a 
patent via PGR.
214
 
 
C. IPR 
Amended by the AIA, 35 U.S.C. § 311 defines IPR’s scope as: “[a] 
petitioner in an inter partes review may request to cancel as unpatentable 
1 or more claims of a patent only on a ground that could be raised under 
section 102 or 103 and only on the basis of prior art consisting of patents 
or printed publications.”
215
  Therefore, IPR cannot be directed to 35 
U.S.C. § 101.
216
  As such, Myriad does not provide a basis for patent 
invalidation in an IPR because the holding that DNA sequences are 
unpatentable subject matter is not within the scope of an IPR.  As a result, 
Myriad has no notable effect on IPR because the Myriad holding 
implicated changes to the scope of patentable subject matter with respect 
to 35 U.S.C. § 101, and none of the other conditions for patentability.
217
 
Presently, post-Myriad, relevant considerations include how the new 
post-grant proceedings will impact existing and future patents.  However, 
with the AIA, Myriad has a more profound effect on patents issued from 
applications filed after March 16, 2013 because of PGR.
218
  But, this is 
expressly under the condition that a PGR must be requested on or prior 
 
211 See Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the Human 
Genome, 310 SCI. 239–40 (Oct. 14, 2005). 
212 35 U.S.C. § 321 (2012). 
213 Comparison of Post-Grant Proceedings, supra note 155. 
214 Id. 
215 35 U.S.C. § 311 (2012). 
216 Id. 
217 See generally Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 
(2013). 
218 America Invents Act (AIA) Frequently Asked Questions, supra note 168.  
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to nine months after patent issuance.
219
  For newly issued patents, there is 
a nine-month window in which a PGR can be filed, and after that nine-
month window, only an IPR can be filed.
220
  As a result, the terms of the 
statutes will only allow a 35 U.S.C. § 101 cause of action to be brought 
in a PGR, and not in an IPR.
221
  Therefore, for IPR to invalidate patents to 
genes or genetic testing, for example, case law would need to evolve such 
that something previously patentable is now unpatentable in light of 
either 35 U.S.C. §§ 102 or 103 for lack of novelty or obviousness.  The 
case law could feasibly evolve in that way, and the post-Myriad future is 
discussed below. 
 
V.  THE FUTURE OF GENETIC TESTING IN A POST-MYRIAD WORLD 
A. Myriad Defeat in Ambry 
In addition to the landmark Myriad decision finding that patent 
claims to genes covered ineligible subject matter, the Federal Circuit took 
that one step further and held that DNA primers, as compositions of 
matter, were not patentable.
222
  Although cDNA is patentable on the 
grounds that a lab technician “unquestionably creates something new,” 
the court found primers unpatentable despite the fact they are non-
naturally occurring.
223
  The court distinguished the two cases by 
explaining, “‘separating [DNA] from its surrounding genetic material is 
not an act of invention.’”
224
 
Myriad was defeated in a second respect, here, because the Court 
also deemed its methods of screening to be unpatentable.
225
  Comparing a 
patient’s BRCA1 sequence with that of a wild-type, or normal, non-
mutated sequence, and identifying any differences between the two was 
considered a “patent-ineligible abstract idea.”
226
  Although the patented 
method required additional steps such as hybridizing the gene probe and 
amplifying and sequencing it, the court viewed these techniques as “well-
 
219 Id. 
220 Id. 
221 35 U.S.C. §§ 282, 311, 321 (2012). 
222 BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. v. Ambry Genetics 
Corp., 2014 U.S. App. LEXIS 23692, at *8 (Fed. Cir. 2014). 
223 Id. at *8 (quoting Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 
2107, 2119 (2013)). 
224 Id. at *7 (quoting Myriad Genetics, Inc., 133 S. Ct. at 2117). 
225 Id. at *17. 
226 Id. at *17. 
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understood, routine, and conventional techniques” that a scientist would 
have contemplated “when instructed to compare two gene sequences.”
227
  
Therein lies the turning point that may make some fearful of the future. 
While Myriad itself might not be terribly affected as its patents 
expire over the next several years, courts could invalidate patents of other 
patent holders with claims to genetic tests for reasons similar to those in 
Ambry, likely before the Myriad litigation even ends and potentially 
before settlements are reached.
228
  For example, as the court found that at 
least part of Myriad’s genetic test is unpatentable in accordance with 35 
U.S.C. § 101, it might not be that great of a stretch for a court, or the 
USPTO, to find that another genetic test is rendered obvious and 
unpatentable under 35 U.S.C. § 103.
229
  Such a holding implies that a 
previously undiscovered genetic sequence cannot provide the basis for a 
previously known process using the previously unknown genetic 
sequence.  Because of this, it is possible that the genetic testing industry 
would come to a grinding halt as companies’ patents could be brought 
into PGR so long as they were issued within the past nine months. 
Amendments to patents both during and after the PGR proceedings 
are severely restricted and although a PTAB ruling is appealable to the 
Federal Circuit, a final decision to reject some or all patent claims does 
not mean that patent prosecution is reopened.
230
  As a result, a patent 
owner’s lack of a second chance to secure patentability over what was 
once patent-eligible subject matter means that anyone can freely use 
subject matter that was once patented by the company, which devoted 
substantial amounts of money and time to an invention, simply because 
patent law evolved after patents were obtained.
231
  By experiencing such 
an occurrence, or even facing the mere threat of it, companies could stop 
 
227 Id. at *21. 
228 Turna Ray, In Warning to Would-be Competitors, Myriad and BRCA Test Patent 
Holders Sue Ambry, Gene by Gene, GENOMEWEB (July 10, 2013), 
http://www.genomeweb.com/clinical-genomics/warning-would-be-competitors-myriad-and-
brca-test-patent-holders-sue-ambry-gene. 
229 35 U.S.C. §§ 101, 103 (2012); Ambry Genetics Corp., 2014 U.S. App. LEXIS 23692, 
at *8. 
230 See MANUAL OF PATENT EXAMINING PROCEDURE § 1216.01 (9th ed. 2014); Lawrence 
Stahl & Donald Heckenberg, The Limited Ability of a Patent Owner to Amend Claims and 
Present New Claims in Post-Grant and Inter Partes Reviews, FITZPATRICK, CELLA, HARPER 
& SCINTO, 
http://www.fitzpatrickcella.com/DB6EDC/assets/files/News/Fitz_PTO_1_5_8.pdf (last 
visited Mar. 1, 2015). 
231 See Ray, supra note 228. 
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filing patents for genetic tests.  More importantly, companies could stop 
investing in research for the development of new genetic tests.  Although 
hindering research is precisely what Dr. Watson wanted to avoid, it is 
ironically the consequence of a dramatic court ruling that invalidates 
arguably necessary patents.
232
 
Representatives of Myriad adamantly declared, “[t]o create tests for 
hereditary breast cancer and ovarian cancer, our company and its 
investors spent more than $500 million over 17 years before we were able 
to recoup this investment.”
233
  While it is unclear how much of that money 
was used to develop the various aspects of Myriad’s BRCAnalysis test, 
one can safely assume that Myriad would not have invested such a sum 
if it could not have recouped its investment, and ultimately profited, by 
virtue of the exclusive rights granted by patents.
234
 
 
B. Impact of Future Myriad Loss on Post-Grant Proceedings 
In the event Myriad again loses in subsequent litigation, any 
arguments asserted against its patents’ validity could then be used, 
generally, with respect to every seemingly applicable patent through 
post-grant proceedings—either IPR or PGR.  Thus, a loss for Myriad 
means a loss for every other patent that could be invalidated for similar 
reasons. 
The logic of the Court in Prometheus could realistically be applied 
by future courts to hold that certain genetic tests, specifically Myriad’s, 
are wholly unpatentable subject matter.
235
  In Prometheus, just as a natural 
correlation was found to be unpatentable subject matter when it was 
incorporated into a generally known or routine diagnostic test, an 
analogous situation may very well exist where a future court decides that 
isolated human DNA, as unpatentable subject matter, could not be used 
in conjunction with a known diagnostic test to ultimately create 
patentable subject matter.
236
  As a result, any patents granted within the 
past nine months containing claims to a similarly situated genetic test 
 
232 Brief for James D. Watson as Amici Curiae Supporting Neither Party, Ass’n of 
Molecular Pathology v. USPTO, No. 2010-1406, 689 F.3d 1303 (2012). 
233 Peter D. Meldrum, Myriad Genetics: Patents Save Lives, Aid Innovation, USA TODAY 
(Apr. 14, 2013 6:59 PM), http://www.usatoday.com/story/opinion/2013/04/14/myriad-
genetics-supreme-court-editorials-debates/2082553/. 
234 See 35 U.S.C. § 154(a)(2) (2012). 
235 See Mayo Collaborative Servs. v. Prometheus Labs., 132 S. Ct. 1289 (2012). 
236 See id. at 1305. 
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would be directly affected by the new changes to post-grant proceedings 
wherein PGR could be instituted under 35 U.S.C. § 101 grounds for 
invalidity.
237
  However, a court may invalidate Myriad’s claims for other 
reasons.  For instance, a court could hold, falling in line with Ambry, that 
using a procedurally known genetic test with what is now unpatentable 
isolated human DNA is actually obvious, and therefore unpatentable 
under 35 U.S.C. § 103.
238
  Since the test would be considered unpatentable 
under this section, IPR could then potentially be invoked.  Therefore, any 
patent or claim analogous to what would hypothetically comprise any of 
Myriad’s future invalidated patents or claims, could be subject to post-
grant review proceedings regardless of when they were actually issued.
239
 
 
VI.  CONCLUSION 
Going forward, it is imperative for companies investing time and 
money into the development of genetic tests to be able to obtain patents 
for their tremendous inventions.  Should that cease to be the case, it is 
imaginable that most biotechnology companies will move into other more 
profitable areas of research and innovation.  When that happens, nothing 
short of legislative action could fill the void left behind of billions of 
dollars of research funding that has been invested or that will be invested 
in producing currently patentable inventions. 
Fortunately, this grim outcome can be avoided.  Courts adjudicating 
future cases stemming from the Myriad case-line could feasibly issue 
narrow holdings that will not have a broad-sweeping effect on the rest of 
the industry.  These holdings could be more limited to the facts in the 
respective cases and could avoid redefining the law.  Hopefully the 
industry and the USPTO approach the legislature, or the legislature 
intervenes on its own accord, sooner rather than later, so a solution can 
be reached before it is too late.  At this point, all relevant parties involved 
in clarifying and defining the law are seemingly diverging on these issues, 
further diminishing the hope of a swift resolution. 
Post-grant proceedings fit into the broader picture because they 
present cheaper and quicker options for invalidating another’s patent, and 
courts must tread carefully and be mindful of those proceedings when 
 
237 See 35 U.S.C. § 282 (2012). 
238 Id. § 103; BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. v. Ambry 
Genetics Corp., 2014 U.S. App. LEXIS 23692, at *1 (Fed. Cir. Dec. 17, 2014). 
239 35 U.S.C. §§ 282, 311, 321 (2012). 
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issuing decisions along the Myriad case-line.  For better or worse, such 
court rulings override the views and the guidance provided by the USPTO 
leadership.  When the Federal Circuit or the Supreme Court deems once 
seemingly patentable subject matter to be patent-ineligible, the USPTO’s 
hands are tied and it is bound to harmonize its patent granting practices 
with that court’s decision.  Until the time when the laws are changed, 
courts have the final say, and unfortunately opinions are not always as 
predictable as everyone would expect.  Although it was largely expected 
that the Court in Myriad would find DNA is unpatentable subject matter, 
the Ambry decision coming out merely one day after the USPTO’s second 
interim guidance was a shocking blow that demonstrates the 
extraordinary volatility of patent law practice.  With the ever-present 
uncertainty after these most unfortuitous events unfolded, Ambry must 
not foreshadow a future wherein the patentability of method claims 
hinges on the patentability of the underlying elements as compositions of 
matter. 
 
